Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance)marketing2021-02-12T00:14:15+00:00August 9th, 2017|更多详细信息
Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemiamarketing2021-02-12T00:59:47+00:00July 3rd, 2017|更多详细信息
In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosismarketing2021-02-12T01:06:38+00:00June 20th, 2017|更多详细信息
Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patientsmarketing2021-02-12T00:57:59+00:00June 17th, 2017|更多详细信息
T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencingmarketing2021-02-12T00:17:56+00:00May 30th, 2017|更多详细信息
Invivoscribe Announces Long-Term Collaboration Agreement with Illumina and Plans Release of NGS-based IVD Assay Kitswmm2021-02-26T19:14:04+00:00February 14th, 2017|更多详细信息
Invivoscribe Expands Long-Term Collaboration Agreement to Release FLT3 Mutation and Clonality Assay Kitswmm2021-02-26T19:14:11+00:00January 31st, 2017|更多详细信息
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosiswmm2021-02-26T19:14:23+00:00November 14th, 2016|更多详细信息
Ion Torrent Developers Alliance Program Designed to Speed Targeted NGS Assay Developmentwmm2021-02-26T19:14:30+00:00May 31st, 2016|更多详细信息
German Supreme Court Upholds and Strengthens Invivoscribe FLT3 Patent Positionwmm2021-02-26T19:14:37+00:00March 28th, 2016|更多详细信息